Advances in bioinformatics and genomic data analysis have enabled the identification of cancer antigens that are generally overlooked during immune surveillance; these neoantigens have been shown to possess substantial therapeutic potential

London

Roots Analysis is pleased to announce the publication of its recent study, titled, “Neoantigen Targeted Therapies, 2019-2030.”

The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapeutics over the next decade. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes:
 A detailed assessment of the current market landscape of developers engaged in the development of neoantigen targeted therapies.
 Detailed profiles of developers of neoantigen targeted therapies (shortlisted on the basis of the number of pipeline products).
 A detailed publication analysis of close to 300 peer-reviewed, scientific articles published during the period 2015-2019 (till February), highlighting the research focus within the industry.
 An in-depth analysis of the various patents that have been filed / granted related to neoantigens.
 An analysis of the various partnerships pertaining to neoantigen targeting therapies.
 An analysis of the investments made at various stages of development in companies that are focused on developing neoantigen targeted therapies.
 A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
 Target Disease Indication
 Bone and Cartilage Cancer
 Colorectal Cancer
 Head and Neck Cancer
 Renal Carcinoma
 Hepatocellular Carcinoma
 Lung Cancer
 Gynecological Cancer
 Others
 Type of Treatment
 Personalized
 Off-the-shelf
 Type of Immunotherapy
 Dendritic Cell Vaccine
 DNA / RNA-based Vaccine
 Protein / Peptide-based Vaccine
 TIL-based Therapy
 Route of Administration
 Intradermal
 Intravenous
 Subcutaneous
 Others
 Key Geographical Region
 North America (US)
 Europe (UK, Germany, France, Italy, and Spain
 Rest of the World
 Transcripts of interviews held with the following senior level representatives of stakeholder companies:
Press Release: Variation 1 (Format 2)

 Gabriel Nistor, Chief Scientific Officer, AIVITA Biomedical
 Ella Sorani, Vice President Research and Development, BioLineRx
 Heinz Lubenau, Chief Operating Officer and Co-Founder, VAXIMM

Key companies covered in the report
 Bavarian Nordic
 Genocea Biosciences
 Gradalis
 Immunicum
 Immunovative Therapies
 Iovance Biotherapeutics
 Medigene
 Neon Therapeutics
 Precision Biologics
 Vaxon Biotech

For more information please click on the following link:
https://www.rootsanalysis.com/reports/view_document/neoantigen-targ...

Other Recent Offerings
1. T-Cell Immunotherapies Market (4th Edition), 2019-2030
2. Novel Immuno-Oncology Biomarker Testing Market, 2019-2030
3. Companion Diagnostics Market (2nd Edition), 2019-2030

About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]

Contact Information
Roots Analysis Private Limited
Gaurav Chaudhary
+1 (415) 800 3415
[email protected] 
Press Release: Variation 2 (Format 3)

The neoantigen targeted therapies market is projected to grow at an annualized rate of 57%, till 2030

Roots Analysis has done a detailed study on Neoantigen Targeted Therapies, 2019-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.

To order this 320+ page report, which features 110+ figures and 140+ tables, please visit this link

Key Market Insights
 Presently, over 150 neoantigen targeted therapies are being evaluated for advanced cancer indications and are designed for delivery via different routes of administration
 Several molecules are in early stages of clinical development; based on delivery strategies, variety of vaccines and immunotherapies have been established for targeting personalized and shared antigens
 Over the years, more than 6,000 patents related to neoantigens and affiliated therapies have been granted / filed; this is indicative of the heightened pace of research in this field
 Both industry and academic players are contributing to the innovation, which is evident across published scientific literature focused on multiple targeted therapies for a myriad of cancer indications
 Several investors, having realized the untapped opportunity within this emerging segment of cancer immunotherapy, have invested over USD 7 billion across 150 instances in the period between 2014 and 2019
 The increasing traction in this field is also reflected in the partnership activity; deals inked in the recent past focused on a diverse range of therapies, involving both international and indigenous stakeholders
 The market will receive the required impetus after approval of the first neoantigen targeted therapy; the future growth is likely to be driven by the successful clinical outcomes of the late-stage molecules
 In fact, opinions from industry experts confirm the vast potential of this segment of cancer immunotherapy, capable of targeting personalized / off-the-shelf tumour antigens with multiple types of vaccines and therapies

For more information, please visit https://www.rootsanalysis.com/reports/view_document/neoantigen-targ...

Table of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Concept of Immunotherapy
3.3. History of Cancer Immunotherapy
3.4. Limitations of Cancer Immunotherapy
3.5. Targeting Tumor-Specific Neoantigens
3.5.1. Types of Neoantigens
3.5.2. Role of Neoantigens in Cancer Immunotherapy
3.5.3. Neoantigen Targeted Therapies
3.5.3.1. Identification and Selection of Neoantigens
3.5.3.2. Delivery of Neoantigen Targeted Therapies
3.6. Key Challenges and Future Perspectives

Press Release: Variation 2 (Format 3)

4. MARKET OVERVIEW
4.1. Chapter Overview
4.2. Neoantigen Targeted Therapies: Marketed and Development Pipeline
4.3. Neoantigen Targeted Therapies: Pipeline Analysis
4.3.1. Analysis by Phase of Development
4.3.2. Analysis by Type of Molecule
4.3.3. Analysis by Type of Immunotherapy
4.3.4. Analysis by Type of Therapy
4.3.5. Analysis by Route of Administration
4.3.6. Analysis by Target Disease Indication
4.3.7. Analysis by Type of Neoantigen
4.3.8. Analysis by Line of Therapy
4.3.9. Funnel Analysis: Analysis by Phase of Development, Type of Immunotherapy and Type of Therapy
4.3.10. Heptagon Representation: Analysis by Phase of Development and Route of Administration

4.4. Neoantigen Targeted Therapies: List of Drug Developers
4.4.1. Analysis by Year of Establishment
4.4.2. Analysis by Company Size and Geographical Location
4.4.3. Leading Developers
4.4.4. Analysis by Geography
4.5 Grid Analysis: Analysis by Target Disease Indication, Company Size and Location

5. COMPANY PROFILES: NEOANTIGEN TARGETED THERAPIES
5.1. Chapter Overview
5.2. Bavarian Nordic
5.2.1. Company Overview
5.2.2. Financial Information
5.2.3. Neoantigen Targeted Therapies Portfolio
5.2.4. Recent Collaborations
5.2.5. Future Outlook

5.3. Genocea Biosciences
5.3.1. Company Overview
5.3.2. Financial Information
5.3.3. Neoantigen Targeted Therapies Portfolio
5.3.4. Recent Collaborations
5.3.5. Future Outlook

5.4. Gradalis
5.4.1. Company Overview
5.4.2. Neoantigen Targeted Therapies Portfolio
5.4.3. Recent Collaborations
5.4.4. Future Outlook

5.5. Immunicum
5.5.1. Company Overview
5.5.2. Financial Information
5.5.3. Neoantigen Targeted Therapies Portfolio
5.5.4. Recent Collaborations
5.5.5. Future Outlook

5.6. Immunovative Therapies
5.6.1. Company Overview
5.6.2. Neoantigen Targeted Therapies Portfolio
5.6.3. Recent Collaborations
Press Release: Variation 2 (Format 3)

5.6.4. Future Outlook

5.7. Iovance Biotherapeutics
5.7.1. Company Overview
5.7.2. Financial Information
5.7.3. Neoantigen Targeted Therapies Portfolio
5.7.4. Recent Collaborations
5.7.5. Future Outlook

5.8. MediGene
5.8.1. Company Overview
5.8.2. Financial Information
5.8.3. Neoantigen Targeted Therapies Portfolio
5.8.4. Recent Collaborations
5.8.5. Future Outlook

5.9. Neon Therapeutics
5.9.1. Company Overview
5.9.2. Financial Information
5.9.3. Neoantigen Targeted Therapies Portfolio
5.9.4. Recent Collaborations
5.9.5. Future Outlook

6. PUBLICATION ANALYSIS
6.1. Chapter Overview
6.2. Methodology

6.3. Neoantigen Targeted Therapies: List of Publications
6.3.1. Analysis by Year of Publication
6.3.2. Analysis by Type of Study
6.3.3. Analysis by Study Objective
6.3.4. Analysis by Affiliated Therapies
6.3.5. Analysis by Target Disease Indication
6.3.6. Key Journals: Analysis by Number of Publications

7. PATENT ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Neoantigen Targeted Therapies: Patent Analysis
7.3.1. Analysis by Publication Year
7.3.2. Analysis by Geographical Location
7.3.3. Analysis by CPC Classifications
7.3.4. Analysis by Type of Industry
7.3.5. Emerging Focus Areas
7.3.6. Leading Players: Analysis by Number of Patents

7.4. Neoantigen Targeted Therapies: Patent Benchmarking Analysis
7.4.1. Analysis by Patent Characteristics
7.5. Neoantigen Targeted Therapies: Patent Valuation Analysis

8. PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. Neoantigen Targeted Therapies: List of Partnerships and Collaborations
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
Press Release: Variation 2 (Format 3)

8.3.3. Analysis by Type of Immunotherapy
8.3.4. Analysis by Type of Partnership and Type of Product
8.3.5. Analysis by Type of Partnership and Target Disease Indication
8.3.6. Regional Analysis
8.3.7. Most Active Players: Analysis by Number of Partnerships

9. FUNDING AND INVESTMENT ANALYSIS
9.1. Chapter Overview
9.2. Types of Funding

9.3. Neoantigen Targeted Therapies: Funding and Investment Analysis
9.3.1. Analysis by Number of Instances
9.3.2. Analysis by Amount Invested
9.3.3. Analysis by Type of Funding
9.3.4. Analysis by Amount Invested across Different Types of Therapies
9.3.5. Analysis by Amount Invested across Different Types of Indications
9.3.4. Analysis by Geography
9.3.5. Most Active Players: Analysis by Amount of Funding
9.3.6. Most Active Investors: Analysis by Number of Instances

9.4. Concluding Remarks

10. MARKET FORECAST AND OPPORTUNITY ANALYSIS
10.1 Chapter Overview
10.2. Key Assumptions and Forecast Methodology
10.3. Global Neoantigen Targeted Therapies Market, 2019-2030
10.3.1. Global Neoantigen Targeted Therapies Market: Distribution by Region, 2019-2030 (USD Million)
10.3.2. Global Neoantigen Targeted Therapies Market: Distribution by Target Disease Indication, 2019-
2030 (USD Million)
10.3.2.1Global Neoantigen Targeted Therapies Market for Bone and Cartilage Cancer, 2019-
2030 (USD Million)
10.3.2.2.Global Neoantigen Targeted Therapies Market for Colorectal Cancer, 2019-2030
10.3.2.3.Global Neoantigen Targeted Therapies Market for Gynecological Cancers, 2019-2030 (USD
Million)
10.3.2.4.Global Neoantigen Targeted Therapies Market for Head and Neck Cancer, 2019-2030 (USD
Million)
10.3.2.5.Global Neoantigen Targeted Therapies Market for Hepatocellular Carcinoma, 2019-2030 (USD
Million)
10.3.2.6.Global Neoantigen Targeted Therapies Market for Lung Cancer, 2019-2030 (USD Million)
10.3.2.7.Global Neoantigen Targeted Therapies Market for Renal Carcinoma, 2019-2030 (USD Million)
10.3.2.8.Global Neoantigen Targeted Therapies Market for Other Cancers, 2019-2030 (USD Million)
10.3.3.Global Neoantigen Targeted Therapies Market: Distribution by Type of Neoantigen, 2019-2030
(USD Million)
10.3.3.1.Global Neoantigen Targeted Therapies Market for Personalized Neoantigen Targeted
Therapies, 2019-2030 (USD Million)
10.3.3.2.Global Neoantigen Targeted Therapies Market for Off-the-shelf Neoantigen Targeted Therapies,
2019-2030 (USD Million)

10.3.4. Global Neoantigen Targeted Therapies Market: Distribution by Type of Immunotherapy, 2019-2030 (USD Million)
10.3.4.1.Global Neoantigen Targeted Therapies Market for Dendritic Cell Vaccines, 2019-2030 (USD
Million)
10.3.4.2.Global Neoantigen Targeted Therapies Market for DNA / RNA-based Vaccines, 2019-2030
(USD Million)
10.3.4.3.Global Neoantigen Targeted Therapies Market for Protein / Peptide-based Vaccines, 2019-2030
(USD Million)
Press Release: Variation 2 (Format 3)

10.3.4.4.Global Neoantigen Targeted Therapies Market for TIL-based Therapies, 2019-2030 (USD
Million)

10.3.5. Global Neoantigen Targeted Therapies Market: Distribution by Route of Administration, 2019-2030 (USD Million)
10.3.5.1.Global Neoantigen Targeted Therapies Market for Intradermal Route of Administration, 2019-
2030 (USD Million)
10.3.5.2.Global Neoantigen Targeted Therapies Market for Intravenous Route of Administration, 2019-
2030 (USD Million)
10.3.5.3.Global Neoantigen Targeted Therapies Market for Subcutaneous Route of Administration, 2019-
2030 (USD Million)
10.3.5.4.Global Neoantigen Targeted Therapies Market for Other Routes of Administration, 2019-2030
(USD Million)

10.4. Neoantigen Targeted Therapies Market in the US, 2019-2030 (USD Million)
10.4.1. Neoantigen Targeted Therapies Market in the US: Distribution by Target Disease Indication, 2019-2030 (USD Million)
10.4.2. Neoantigen Targeted Therapies Market in the US: Distribution by Type of Neoantigen, 2019-2030 (USD Million)
10.4.3. Neoantigen Targeted Therapies Market in the US: Distribution by Type of Immunotherapy, 2019-2030 (USD Million)
10.4.3. Neoantigen Targeted Therapies Market in the US: Distribution by Route of Administration, 2019-2030 (USD Million)

10.5. Neoantigen Targeted Therapies Market in the UK, 2019-2030 (USD Million)
10.5.1. Neoantigen Targeted Therapies Market in the UK: Distribution by Target Disease Indication, 2019-2030 (USD Million)
10.5.2. Neoantigen Targeted Therapies Market in the UK: Distribution by Type of Neoantigen, 2019-2030 (USD Million)
10.5.3. Neoantigen Targeted Therapies Market in the UK: Distribution by Type of Immunotherapy, 2019-2030 (USD Million)
10.5.4. Neoantigen Targeted Therapies Market in the UK: Distribution by Route of Administration, 2019-2030 (USD Million)

10.6. Neoantigen Targeted Therapies Market in Germany, 2019-2030 (USD Million)
10.6.1. Neoantigen Targeted Therapies Market in Germany: Distribution by Target Disease Indication, 2019-2030 (USD Million)
10.6.2. Neoantigen Targeted Therapies Market in Germany: Distribution by Type of Neoantigen, 2019-2030 (USD Million)
10.6.3. Neoantigen Targeted Therapies Market in Germany: Distribution by Type of Immunotherapy, 2019-2030 (USD Million)
10.6.4. Neoantigen Targeted Therapies Market in Germany: Distribution by Route of Administration, 2019-2030 (USD Million)

10.7. Neoantigen Targeted Therapies Market in France, 2019-2030 (USD Million)
10.7.1. Neoantigen Targeted Therapies Market in France: Distribution by Target Disease Indication, 2019-2030 (USD Million)
10.7.2. Neoantigen Targeted Therapies Market in France: Distribution by Type of Neoantigen, 2019-2030 (USD Million)
10.7.3. Neoantigen Targeted Therapies Market in France: Distribution by Type of Immunotherapy, 2019-2030 (USD Million)
10.7.4. Neoantigen Targeted Therapies Market in France: Distribution by Route of Administration, 2019-2030 (USD Million)

10.8. Neoantigen Targeted Therapies Market in Italy, 2019-2030 (USD Million)

Press Release: Variation 2 (Format 3)

10.8.1. Neoantigen Targeted Therapies Market in Italy: Distribution by Target Disease Indication, 2019-2030 (USD Million)
10.8.2. Neoantigen Targeted Therapies Market in Italy: Distribution by Type of Neoantigen, 2019-2030 (USD Million)
10.8.3. Neoantigen Targeted Therapies Market in Italy: Distribution by Type of Immunotherapy, 2019-2030 (USD Million)
10.8.4. Neoantigen Targeted Therapies Market in Italy: Distribution by Route of Administration, 2019-2030 (USD Million)

10.9. Neoantigen Targeted Therapies Market in Spain, 2019-2030 (USD Million)
10.9.1. Neoantigen Targeted Therapies Market in Spain: Distribution by Target Disease Indication, 2019-2030 (USD Million)
10.9.2. Neoantigen Targeted Therapies Market in Spain: Distribution by Type of Neoantigen, 2019-2030 (USD Million)
10.9.3. Neoantigen Targeted Therapies Market in Spain: Distribution by Type of Immunotherapy, 2019-2030 (USD Million)
10.9.4. Neoantigen Targeted Therapies Market in Spain: Distribution by Route of Administration, 2019-2030 (USD Million)

10.10. Neoantigen Targeted Therapies Market in Rest of the World, 2019-2030 (USD Million)
10.10.1.Neoantigen Targeted Therapies Market in Rest of the World: Distribution by Target Disease
Indication, 2019-2030 (USD Million)
10.10.2.Neoantigen Targeted Therapies Market in Rest of the World: Distribution by Type of Neoantigen,
2019-2030 (USD Million)
10.10.3.Neoantigen Targeted Therapies Market in Rest of the World: Distribution by Type of
Immunotherapy, 2019-2030 (USD Million)
10.10.4.Neoantigen Targeted Therapies Market in Rest of the World: Distribution by Route of
Administration, 2019-2030 (USD Million)

11. CONCLUDING REMARKS

12. EXECUTIVE INSIGHTS
12.1. Chapter Overview
12.2. AIVITA Biomedical
12.2.1. Company Snapshot
12.2.2. Interview Transcript: Gabriel Nistor (Chief Scientific Officer)

12.3. BioLineRx
12.3.1. Company Snapshot
12.3.2. Interview Transcript: Ella Sorani (Vice President Research and Development)

12.3. VAXIMM
12.3.1. Company Snapshot
12.3.2. Interview Transcript: Heinz Lubenau (Chief Operating Officer and Co-Founder)

13. APPENDIX 1: TABULATED DATA

14. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

Contact Details:
Gaurav Chaudhary
+1 (415) 800 3415
[email protected]